ClinicalTrials.gg
CompletedNCT00055523Updated Aug 15, 2006

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

A Phase 2 interventional study of Adalimumab (D2E7) in Crohn's Disease, sponsored by Abbott. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2006-08-15.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
7th of 42
300 · median 143
Started
2002
with 2 others
Phase 2
2 of 42
none open now
Registered
2nd of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 7th largest by enrollment, is one of 3 that started in 2002, is one of 2 in phase 2, and was the 2nd registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Crohn's disease
  • CDAI score at baseline of between 220 and 450
  • Normal laboratory parameters
  • Willing and able to give

Exclusion criteria

Exclusion:

  • Diagnosis of ulcerative colitis
  • Women cannot be pregnant or breastfeeding
  • No previous use of infliximab or other anti-TNF antagonists
  • No previous history of tuberculosis or listeria infection
  • No previous history of cancer other than successfully treated skin cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. comparison of the induction of clinical remission

  2. (achievement of a CDAI <150) of adalimumab 40 mg and 80 mg vs. placebo at Week 4.

07

Study locations

43 sites
  • Gastroenterology Associates of the East Bay
    Berkeley, California 94705, United States
  • Long Beach Gastroenterology Assoc.
    Long Beach, California 90806, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92123, United States
  • Gastroenterology Assoc. of Fairfield Co.
    Bridgeport, Connecticut 06606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Assoc.
    Atlanta, Georgia 30342, United States
  • Southeastern Digestive & Liver Disease
    Savannah, Georgia 31404, United States
  • Northwest Gastroenterologists, S.C.
    Arlington Heights, Illinois 600005, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Drug Research Services, Inc.
    Metairie, Louisiana 70001, United States
  • LSU School of Medicine
    New Orleans, Louisiana 70115, United States
  • Digestive Disorders Associates
    Annapolis, Maryland 21401, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 002115, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Mayo Clinic and Mayo Foundation
    Rochester, Minnesota 55905, United States
  • Gastroenterology and Hepatology
    Kansas City, Missouri 64131, United States
  • Glenn Gordon, MD
    Mexico, Missouri 65265, United States
  • Deaconess Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Gastroenterology Specialties, P.C.
    Lincoln, Nebraska 68503, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NY Center for Clinical Research
    Lake Success, New York 11042, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Daniel Present
    New York, New York 10029, United States
  • Rochester Institute for Digestive Diseases
    Rochester, New York 14607, United States
  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology and Hepatology
    Charlotte, North Carolina 28207, United States
  • Carolina Research Associates
    Charlotte, North Carolina 28262, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Digestive Health Specialists
    Winston-Salem, North Carolina 27103, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • Oklahoma Foundation for Digestive Disease
    Oklahoma City, Oklahoma 73104, United States
  • Research Solutions
    Tulsa, Oklahoma 74104, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Peter Molloy, MD
    Pittsburgh, Pennsylvania 15224, United States
  • Diseases of the Digestive System
    Chattanooga, Tennessee 37421, United States
  • Nashville Medical Research Institute
    Nashville, Tennessee 37205, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22902, United States
  • Northwest Gastroenterology
    Bellevue, Washington 98004, United States
  • Inland Empire Gastroenterology
    Spokane, Washington 99204, United States
  • Tacoma Digestive Disease Center
    Tacoma, Washington 98405, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53702, United States
08

References and documents

Publications

  • Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OO, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012 Dec;18(12):2209-17. doi: 10.1002/ibd.22910. Epub 2012 Feb 16. PubMed 22344964 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00055523
Lead sponsor
Abbott
First posted
Mar 6, 2003
Start date
Apr 2002
Last update
Aug 15, 2006

Study contacts

Stephen B Hanauer, MD
principal investigator · University of Chicago Department of Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion